Getinge Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Getinge verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 10.4%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 17.9%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 3.5%. Die Eigenkapitalrendite von Getinge beträgt 8.2% und die Nettomargen betragen 7.8%.

Wichtige Informationen

10.4%

Wachstumsrate der Gewinne

10.4%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie	6.2%
Wachstumsrate der Einnahmen	3.5%
Eigenkapitalrendite	8.2%
Netto-Marge	7.8%
Nächste Ertragsaktualisierung	18 Oct 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Sep 19

Pinning Down Getinge AB (publ)'s (STO:GETI B) P/E Is Difficult Right Now

Aug 23

An Intrinsic Calculation For Getinge AB (publ) (STO:GETI B) Suggests It's 49% Undervalued

Aug 08

Getinge AB (publ) Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

Jul 21

We Like These Underlying Return On Capital Trends At Getinge (STO:GETI B)

Jun 27

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

May 11

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 25

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

Apr 15

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Mar 30

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Mar 29

The Return Trends At Getinge (STO:GETI B) Look Promising

Mar 21

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Feb 04

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Jan 20

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Jan 05

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Dec 20

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Dec 05

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Oct 06

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Sep 21

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Sep 03

Is Getinge (STO:GETI B) A Risky Investment?

Jun 28

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Jun 15

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

Jun 01

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

May 05

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Apr 05

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Feb 28

Aufschlüsselung der Einnahmen und Ausgaben

Wie Getinge Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OM:GETI B Einnahmen, Ausgaben und Erträge (SEK Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	33,328	2,584	10,235	1,292
31 Mar 24	32,199	2,285	9,956	1,207
31 Dec 23	31,827	2,412	9,681	1,192
30 Sep 23	30,423	2,251	9,260	1,258
30 Jun 23	29,756	2,154	9,004	1,232
31 Mar 23	29,251	2,543	8,672	1,228
31 Dec 22	28,292	2,491	8,386	1,185
30 Sep 22	27,781	2,707	8,240	1,008
30 Jun 22	27,146	2,665	8,060	952
31 Mar 22	27,062	2,860	8,005	903
31 Dec 21	27,049	2,970	7,927	851
30 Sep 21	27,900	3,292	8,090	891
30 Jun 21	29,571	3,916	8,221	899
31 Mar 21	29,955	3,612	8,390	1,035
31 Dec 20	29,819	3,239	8,783	1,033
30 Sep 20	29,478	3,050	8,830	952
30 Jun 20	27,738	1,878	8,958	920
31 Mar 20	27,044	1,487	9,017	757
31 Dec 19	26,559	1,222	8,854	762
30 Sep 19	25,951	1,030	8,644	744
30 Jun 19	25,398	-632	8,628	724
31 Mar 19	24,852	-654	8,455	718
31 Dec 18	24,172	-967	8,292	691
30 Sep 18	23,653	-727	8,157	676
30 Jun 18	22,914	847	7,867	670
31 Mar 18	22,552	676	7,747	642
31 Dec 17	22,495	1,096	7,740	594
30 Sep 17	17,061	596	5,858	504
30 Jun 17	19,046	390	6,360	496
31 Mar 17	20,604	701	6,783	500
31 Dec 16	22,170	698	7,201	538
30 Sep 16	29,650	1,203	9,512	628
30 Jun 16	29,646	1,462	9,561	624
31 Mar 16	29,900	1,410	9,777	607
31 Dec 15	30,235	1,390	9,905	598
30 Sep 15	29,303	1,429	9,722	574
30 Jun 15	28,603	1,622	9,471	574
31 Mar 15	27,749	1,850	9,069	591
31 Dec 14	26,669	1,433	8,596	597
30 Sep 14	25,843	1,672	8,403	620
30 Jun 14	25,468	1,718	8,180	620
31 Mar 14	25,157	1,776	8,040	612
31 Dec 13	25,287	2,285	7,962	619
30 Sep 13	25,345	2,105	8,061	602

Qualität der Erträge: GETI B hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: GETI BDie aktuellen Gewinnspannen (7.8%) sind höher als im letzten Jahr (7.2%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: GETI B ist in den letzten 5 Jahren profitabel geworden und hat seinen Gewinn um 10.4% pro Jahr gesteigert.

Beschleunigtes Wachstum: GETI BDas Gewinnwachstum des Unternehmens im letzten Jahr (20%) übertrifft seinen 5-Jahres-Durchschnitt (10.4% pro Jahr).

Erträge im Vergleich zur Industrie: GETI B Das Gewinnwachstum im vergangenen Jahr (20%) übertraf nicht die Entwicklung der Branche Medical Equipment 38.1% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: GETI BDie Eigenkapitalrendite des Unternehmens (8.2%) wird als niedrig angesehen.

Getinge Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Independent Director recently bought kr1.1m worth of stock

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Independent Chairman recently bought kr4.3m worth of stock

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Pinning Down Getinge AB (publ)'s (STO:GETI B) P/E Is Difficult Right Now

An Intrinsic Calculation For Getinge AB (publ) (STO:GETI B) Suggests It's 49% Undervalued

Getinge AB (publ) Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

We Like These Underlying Return On Capital Trends At Getinge (STO:GETI B)

Investor sentiment deteriorates as stock falls 18%

Getinge (STO:GETI B) Seems To Use Debt Quite Sensibly

Results: Getinge AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Upcoming dividend of kr4.40 per share

Is Getinge AB (publ) (STO:GETI B) Trading At A 41% Discount?

The Getinge AB (publ) (STO:GETI B) Annual Results Are Out And Analysts Have Published New Forecasts

Getinge's (STO:GETI B) Upcoming Dividend Will Be Larger Than Last Year's

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

The Return Trends At Getinge (STO:GETI B) Look Promising

Dividend increased to kr4.40

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Analysts Are Updating Their Getinge AB (publ) (STO:GETI B) Estimates After Its Full-Year Results

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

There's Reason For Concern Over Getinge AB (publ)'s (STO:GETI B) Price

Here's Why Getinge (STO:GETI B) Can Manage Its Debt Responsibly

Price target increased by 8.4% to kr229

Getinge AB (publ)'s (STO:GETI B) Intrinsic Value Is Potentially 42% Above Its Share Price

Returns On Capital Are Showing Encouraging Signs At Getinge (STO:GETI B)

Price target increased by 7.0% to kr220

Consensus EPS estimates increase by 23%

Third quarter 2023 earnings: Revenues exceed analyst expectations

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge (STO:GETI B) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 37% Undervaluation?

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge's (STO:GETI B) Returns On Capital Are Heading Higher

Second quarter 2023 earnings: Revenues exceed analyst expectations

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Is Getinge (STO:GETI B) A Risky Investment?

Consensus EPS estimates fall by 13%

Investor sentiment deteriorates as stock falls 22%

Is There An Opportunity With Getinge AB (publ)'s (STO:GETI B) 23% Undervaluation?

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Investors Will Want Getinge's (STO:GETI B) Growth In ROCE To Persist

At kr252, Is Getinge AB (publ) (STO:GETI B) Worth Looking At Closely?

First quarter 2023 earnings: Revenues exceed analyst expectations

Now 22% undervalued

Upcoming dividend of kr4.25 per share at 1.6% yield

Getinge (STO:GETI B) Has Announced That It Will Be Increasing Its Dividend To SEK4.25

Slowing Rates Of Return At Getinge (STO:GETI B) Leave Little Room For Excitement

Is Getinge AB (publ) (STO:GETI B) Trading At A 42% Discount?

Getinge (STO:GETI B) Is Paying Out A Larger Dividend Than Last Year

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Is Getinge (STO:GETI B) Using Too Much Debt?

Full year 2022 earnings: EPS misses analyst expectations

Getinge AB (Publ) Proposes Dividend

Price target decreased to kr249

When Should You Buy Getinge AB (publ) (STO:GETI B)?

Price target decreased to kr272

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Are Investors Undervaluing Getinge AB (publ) (STO:GETI B) By 49%?

Third quarter 2022 earnings: Revenues in line with analyst expectations